Form 4: PLUS THERAPEUTICS CFO Acquires Shares via RSU Vesting

PLUS THERAPEUTICS CFO Andrew Sims acquired 38,323 shares of common stock through the vesting of Restricted Stock Units on January 1, 2026.

Summary

• Andrew Sims, Chief Financial Officer of PLUS THERAPEUTICS, INC. (PSTV), acquired 38,323 shares of the company's common stock.
• The acquisition took place on January 1, 2026, and was a result of the vesting of Restricted Stock Units (RSUs).
• The transaction price for the acquired shares was $0, as it represents the conversion of previously granted RSUs into common stock.
• Following this transaction, Mr. Sims directly beneficially owns 106,461 shares of common stock.
• He also continues to hold 383,232 derivative securities in the form of Restricted Stock Units.
• The RSU grant vests in twelve substantially equal quarterly installments, with the initial vesting period commencing on October 1, 2025.

Sentiment

Score: 6

Explanation: The filing reports a routine, expected insider transaction (RSU vesting) which increases the CFO's direct ownership, generally viewed as a neutral to slightly positive event for shareholder alignment.

Positives

• Increases the direct beneficial ownership of common stock by the Chief Financial Officer, further aligning management's interests with those of shareholders.
• Represents a routine, scheduled compensation event, indicating the ongoing execution of executive compensation plans.

Future Outlook

The remaining Restricted Stock Units held by the CFO are expected to vest in future quarterly installments, continuing the pre-determined compensation schedule.

Industry Context

This filing is a routine insider transaction report and does not provide specific industry context or trends. It reflects an individual executive's compensation and ownership stake within the company.

Stakeholder Impact

• Shareholders: Increased alignment of management's interests with shareholders due to higher direct ownership by the CFO.
• Employees: Reflects the execution of established executive compensation plans.

Next Steps

• Future quarterly installments of RSU vesting for the remaining 383,232 derivative securities held by the CFO.

Key Dates

Keywords

PSTV, PLUS THERAPEUTICS, Form 4, RSU Vesting, Insider Transaction, Andrew Sims, CFO, Common Stock